FR2609393A1 - Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared - Google Patents
Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared Download PDFInfo
- Publication number
- FR2609393A1 FR2609393A1 FR8802164A FR8802164A FR2609393A1 FR 2609393 A1 FR2609393 A1 FR 2609393A1 FR 8802164 A FR8802164 A FR 8802164A FR 8802164 A FR8802164 A FR 8802164A FR 2609393 A1 FR2609393 A1 FR 2609393A1
- Authority
- FR
- France
- Prior art keywords
- acid
- pharmaceutical
- composition
- cosmetic
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 239000002537 cosmetic Substances 0.000 title claims abstract description 18
- 239000000126 substance Substances 0.000 title claims abstract description 16
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 13
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 13
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 11
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 10
- 239000000463 material Substances 0.000 title claims abstract description 7
- 239000002502 liposome Substances 0.000 claims abstract description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 48
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 32
- 239000012153 distilled water Substances 0.000 claims description 24
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 24
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 24
- 229960002216 methylparaben Drugs 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 235000012000 cholesterol Nutrition 0.000 claims description 16
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 102000003886 Glycoproteins Human genes 0.000 claims description 6
- 108090000288 Glycoproteins Proteins 0.000 claims description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 210000004381 amniotic fluid Anatomy 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 102000004895 Lipoproteins Human genes 0.000 claims description 5
- 108090001030 Lipoproteins Proteins 0.000 claims description 5
- 150000001412 amines Chemical group 0.000 claims description 5
- 210000000941 bile Anatomy 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 210000002826 placenta Anatomy 0.000 claims description 5
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 4
- 108010087806 Carnosine Proteins 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-N PYRUVIC-ACID Natural products CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 4
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229940044199 carnosine Drugs 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 235000013345 egg yolk Nutrition 0.000 claims description 4
- 210000002969 egg yolk Anatomy 0.000 claims description 4
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 4
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 claims description 4
- 150000003408 sphingolipids Chemical class 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 229920002527 Glycogen Polymers 0.000 claims description 3
- 108010076876 Keratins Proteins 0.000 claims description 3
- 102000011782 Keratins Human genes 0.000 claims description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 3
- 102000007982 Phosphoproteins Human genes 0.000 claims description 3
- 108010089430 Phosphoproteins Proteins 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 239000006035 Tryptophane Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 229940096919 glycogen Drugs 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 229960003104 ornithine Drugs 0.000 claims description 3
- 229940107700 pyruvic acid Drugs 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 2
- 108010085443 Anserine Proteins 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 102100027992 Casein kinase II subunit beta Human genes 0.000 claims description 2
- 101710158100 Casein kinase II subunit beta Proteins 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 2
- 102000016942 Elastin Human genes 0.000 claims description 2
- 108010014258 Elastin Proteins 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000195480 Fucus Species 0.000 claims description 2
- 108010068370 Glutens Proteins 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 claims description 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-Citrulline Natural products NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 2
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 102000015728 Mucins Human genes 0.000 claims description 2
- 108010063954 Mucins Proteins 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 2
- 108010058846 Ovalbumin Proteins 0.000 claims description 2
- 241000210053 Potentilla elegans Species 0.000 claims description 2
- 102000007327 Protamines Human genes 0.000 claims description 2
- 108010007568 Protamines Proteins 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 241000006364 Torula Species 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 2
- 235000020244 animal milk Nutrition 0.000 claims description 2
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 244000309466 calf Species 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229960004203 carnitine Drugs 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 claims description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 2
- 102000034240 fibrous proteins Human genes 0.000 claims description 2
- 108091005899 fibrous proteins Proteins 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 108060003196 globin Proteins 0.000 claims description 2
- 102000018146 globin Human genes 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002591 hydroxyproline Drugs 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229940051875 mucins Drugs 0.000 claims description 2
- 229940092253 ovalbumin Drugs 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 108060006613 prolamin Proteins 0.000 claims description 2
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 claims description 2
- 229940048914 protamine Drugs 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 2
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 102000006947 Histones Human genes 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 102000012404 Orosomucoid Human genes 0.000 claims 1
- 108010061952 Orosomucoid Proteins 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 239000012071 phase Substances 0.000 description 49
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 239000008346 aqueous phase Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000002304 perfume Substances 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 229940105132 myristate Drugs 0.000 description 6
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 239000005662 Paraffin oil Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940029614 triethanolamine stearate Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229930183167 cerebroside Natural products 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- POQRWMRXUOPCLD-UHFFFAOYSA-N N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)NC(C(O)C=CCCCCCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O POQRWMRXUOPCLD-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010015053 lipovitellin Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 239000011252 protective cream Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
Description
Composition notamment utile comme matière de base pour la préparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmétiques comprenant une substance azotée, notamment aminoacides, oligo- ou polypeptides, protéines, et Leurs dérivés, et composition pharmaceutique ou cosmétique ainsi préparée.Composition in particular useful as a base material for the preparation of pharmaceutical, in particular dermatological and / or cosmetic compositions comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared.
La présente invention concerne essentiellement une composition notamment utile comme matière de base pour la préparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmétiques comprenant une substance azotée, notamment aminoacides, oligo- ou polypeptides, protéines, et leurs dérivés, et composition pharmaceutique ou cosmétique ainsi préparée. The present invention essentially relates to a composition in particular useful as a base material for the preparation of pharmaceutical compositions, in particular dermatological and / or cosmetic compositions comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition. thus prepared.
Plus particulièrement, l'invention concerne une composition notamment utile comme matière de base pour la préparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmétiques, caractérisée en ce qu'elle comprend une substance azotée, notamment un aminoacide, un oligo- ou polypeptide, une protéine, et leurs dérivés. More particularly, the invention relates to a composition in particular useful as a base material for the preparation of pharmaceutical compositions, in particular dermatological and / or cosmetic, characterized in that it comprises a nitrogenous substance, in particular an amino acid, an oligo- or polypeptide, a protein, and their derivatives.
Ces substances azotées selon l'invention, oligo- ou polypeptides, protéines et leurs dérivés, pourront être issues du règne animal en étant extraites d'éléments ou organes tels que le thymus, la rate, le plasma et le sérum sanguins, le foie, la bile, les ovaires, le placenta, le lait, le liquide amniotique, la peau, les plumes, les poils, les crins, ou issues de bactéries, de levures, de fungi, ou encore issues de végétaux terrestres ou d'algues. These nitrogenous substances according to the invention, oligo- or polypeptides, proteins and their derivatives, can be derived from the animal kingdom by being extracted from elements or organs such as the thymus, the spleen, the blood plasma and serum, the liver, bile, ovaries, placenta, milk, amniotic fluid, skin, feathers, hair, hair, or from bacteria, yeast, fungi, or from terrestrial plants or algae.
Ces extraits pourront être préparés par simple extraction, soit encore par un procédé biotechnologique. These extracts can be prepared by simple extraction, or again by a biotechnological process.
Ces substances azotées pourront être préparées suivant un processus comportant une phase d'extraction suivie ou non d'un isolement des constituants natifs, soit d'une phase d'hydrolyse par adjonction d'enzymes ou complexes enzymatiques protéolytiques, par autolyse, etc. These nitrogenous substances can be prepared according to a process comprising an extraction phase followed or not by an isolation of the native constituents, or a hydrolysis phase by addition of enzymes or proteolytic enzyme complexes, by autolysis, etc.
Tous ces procédés sont bien connus à L'homme de l'art et n'ont donc pas besoin d'être décrits en détail ici. All these methods are well known to those skilled in the art and therefore do not need to be described in detail here.
Selon une caractéristique avantageuse de L'invention, les aminoacides précités répondent à la formule générale suivante
- où R sera une chaîne aliphatique linéaire ou ramifiée, saturée,
pouvant porter un ou plusieurs atomes de carbone substitués par
une fonction méthyle.According to an advantageous characteristic of the invention, the above-mentioned amino acids correspond to the following general formula
- where R will be a saturated linear or branched aliphatic chain,
may bear one or more carbon atoms substituted by
a methyl function.
Exemple GLYCINE (R = CH2) ALANINE (R = CH3 - CH -)
et ses dérivés tels que acide a-amino-butyrique acide γ- amino-butyrique
acide 6-amino-isobutyrique
éthanolamine . VALINE . LEUCINE . ISOLEUCINE
- où R pourra être une chaîne aliphatique saturée, linéaire ou
ramifiée, pouvant porter un ou plusieurs atomes de carbone subs
titués par une fonction alcool, par exemple SERINE (R = - CH - CH2QH) . THREONINE (R = - CH - CHOH - CH3) - où R pourra être une chaîne aliphatique saturée, linéaire,
soufrée . CYSTEINE (R. = - CH - CH2 - SH)
son dimère, la cystine et ses dérivés : taurine et ac. cystéine . METHIONINE (R = - CH - CH2 - CH2 - S - CH3). Example GLYCINE (R = CH2) ALANINE (R = CH3 - CH -)
and its derivatives such as α-amino-butyric acid γ - amino-butyric
6-amino-isobutyric acid
ethanolamine. VALINE. LEUCINE. ISOLEUCIN
- where R can be a saturated, linear or aliphatic chain
branched, capable of carrying one or more carbon atoms
with an alcohol function, for example SERINE (R = - CH - CH2QH). THREONINE (R = - CH - CHOH - CH3) - where R could be a saturated, linear aliphatic chain,
sulfur. CYSTEINE (R. = - CH - CH2 - SH)
its dimer, cystine and its derivatives: taurine and ac. cysteine. METHIONINE (R = - CH - CH2 - CH2 - S - CH3).
- où R pourra être une chaine aliphatique saturée, linéaire,
portant un groupement carboxyle . ACIDE ASPARTIQUE (R = - CH - CH2 - COOH) ACIDE GLUTAMIQUE (R = - CH - CH2 - CH2 - COOH)
(et son dérivé de cyclisation : l'acide pyrrolidone carboxylique)
Le radical COOH pourra être substitué par une fonction amine . ASPARAGINE (R = - CH - CH2 - CO - NH2) . GLUTAMINE (R = - CH - CH2 - CH2 - CO - NH2) - où R pourra être une chaîne aliphatique saturée ou non, linéaire,
substituée ou non, portant une fonction amine terminale ACIDE α,ss-DIAMINOPROPIONIQUE (R= -CH -CH2- NH2) . ACIDE α,ss-DIAMINOBUTYRIQUE CR=-CH2--H2--H2--NH2) . ORNITHINE (R= -CH - CH2 - CH2--CH2--NH2-
LYSINE (R=--CH--CH2--CH2--CH2--NH2)
2 2-CH2-NH2) .HYDROXYLYSINE (R=cH2-CH2-CH0HrH2H2)
- où R est une chaîne aliphatique comportant un cycle . PHENYLALANINE TYROSINE . HISTIDINE
et ses dérivés
- 1-methylhistidine
- 3-méthylhistidine . TRYPTOPHANE
- où R est engagé avec la fonction NH2 dans un cycle pyrrolique
. PROLINE
. HYDROXYPROLINE
Ces aminoacides et leurs dérivés pourront être utilisés seuls ou combinés entre eux en un nombre quelconque sans la formation de nouvelles substances, ou avec formation de nouvelles substances ou entités chimiques de manière à former des oligo peptides, polypeptides ou protéines selon le nombre d'unités combinées.- where R could be a saturated, linear aliphatic chain,
carrying a carboxyl group. ASPARTIC ACID (R = - CH - CH2 - COOH) GLUTAMIC ACID (R = - CH - CH2 - CH2 - COOH)
(and its cyclization derivative: pyrrolidone carboxylic acid)
The COOH radical may be substituted by an amine function. ASPARAGIN (R = - CH - CH2 - CO - NH2). GLUTAMINE (R = - CH - CH2 - CH2 - CO - NH2) - where R could be a saturated or unsaturated, linear aliphatic chain,
substituted or unsubstituted, carrying a terminal amine function ACID α, ss-DIAMINOPROPIONIQUE (R = -CH -CH2- NH2). ACID α, ss-DIAMINOBUTYRIC CR = -CH2 - H2 - H2 - NH2). ORNITHINE (R = -CH - CH2 - CH2 - CH2 - NH2-
LYSINE (R = - CH - CH2 - CH2 - CH2 - NH2)
2 2-CH2-NH2) .HYDROXYLYSINE (R = cH2-CH2-CH0HrH2H2)
- where R is an aliphatic chain comprising a cycle. PHENYLALANINE TYROSINE. HISTIDINE
and its derivatives
- 1-methylhistidine
- 3-methylhistidine. TRYPTOPHANE
- where R is engaged with the NH2 function in a pyrrolic cycle
. PROLINE
. HYDROXYPROLINE
These amino acids and their derivatives can be used alone or combined with one another in any number without the formation of new substances, or with the formation of new substances or chemical entities so as to form oligo peptides, polypeptides or proteins depending on the number of units combined.
Selon une caractéristique particulièrement avantageuse de l'invention, les dérivés d'aminoacides utilisés selon l'invention comme substances azotées sont choisis parmi le groupe consistant en - Les bases aliphatiques tel Les que
. METHYLAMINE
. ISO-AMYLAMINE
. TETRAMETHYLENEDIAMINE
.PENTAMETHYLENEDIAMINE - Les bétaines, telles que la bétaine proprement dite, la carnitine - L-citrulline - l'urée - l'acide urocanique - l'acide pyrroglutamique - L'acide pyruvique - L'acide oc-amino-acrylique - l'acide oc-cétoburyrique - L'acide P-OH-méthylglutarique - l'homocystéine - l'acide homogentisique - l'acide indolepyruvique - l'acide cétoglutarique - l'acide aminoadipique - la mercapto-2-thiohistidine - l'éthanolamine
Selon une autre caractéristique avantageuse de l'invention, ces aminoacides ou leurs dérivés peuvent être obtenus à l'état naturel, ou après hydrolyse enzymatique ménagée (en particulier par une hydrolyse trypsique) à partir de - les fractions sanguines animales, en particulier bovines ou
équines, que ce soit le plasma total ou le sérum total, ou leurs
fractions purifiées enrichies ou concentrées en certains
composants, - le placenta animal, - le liquide amniotique animal, le lait animal, - les liquides biliaires, - les extraits de levure, en particulier les extraits de saccharo
myces, de torula, - les extraits de bactéries, en particulier extraits de Klebsiella,
Bacillus, - dans certains végétaux, en particulier au niveau des graines
comme oligo- ou polypeptides, protéines et leurs dérivés.According to a particularly advantageous characteristic of the invention, the amino acid derivatives used according to the invention as nitrogenous substances are chosen from the group consisting of - Aliphatic bases such as
. METHYLAMINE
. ISO-AMYLAMINE
. TETRAMETHYLENEDIAMINE
.PENTAMETHYLENEDIAMINE - Betaines, such as betaine itself, carnitine - L-citrulline - urea - urocanic acid - pyrroglutamic acid - Pyruvic acid - Oc-amino-acrylic acid - oc-ketoburyric acid - P-OH-methylglutaric acid - homocysteine - homogentisic acid - indolepyruvic acid - ketoglutaric acid - aminoadipic acid - mercapto-2-thiohistidine - ethanolamine
According to another advantageous characteristic of the invention, these amino acids or their derivatives can be obtained in the natural state, or after controlled enzymatic hydrolysis (in particular by tryptic hydrolysis) from - animal blood fractions, in particular bovine or
equines, whether total plasma or total serum, or their
purified fractions enriched or concentrated in certain
components, - animal placenta, - animal amniotic fluid, animal milk, - bile fluids, - yeast extracts, especially saccharo extracts
myces, torula, - extracts of bacteria, in particular extracts of Klebsiella,
Bacillus, - in some plants, especially in seeds
as oligo- or polypeptides, proteins and their derivatives.
On pourra utiliser le glutathion, ayant une chaîne courte composée de trois acides
aminés, - la carnosine et L'ansérine, composés cycliques du muscle, - les protéines de faible poids moléculaire, type protamine
CPM = 2000 à 5000), l'histone, les globines, les prolamines et
les glutélines végétales extraites des graines, ainsi que les
oligopeptides des liquides biliaires ou amniotiques, l'albumine, qu'elle soit animale ou végétale, - les scléroprotéines, en particulier
* le collagène natif
* l'élastine native
* la fibroine native
* la kératine native
De même, on pourra utiliser les hétéroprotéines suivantes les phosphoprotéines les glycoprotéines - les lipoprotéines
Parmi les phosphoprotéines, on pourra utiliser la caséine du lait, la vitelline, lavitellénine et la phosvitine du jaune d'oeuf.We can use glutathione, having a short chain made up of three acids
amines, - carnosine and anserine, cyclic muscle compounds, - low molecular weight proteins, protamine type
CPM = 2000 to 5000), histone, globins, prolamins and
the vegetable glutelins extracted from the seeds, as well as the
oligopeptides of bile or amniotic fluids, albumin, whether animal or vegetable, - scleroproteins, in particular
* native collagen
* native elastin
* native fibroin
* native keratin
Similarly, we can use the following heteroproteins phosphoproteins glycoproteins - lipoproteins
Among the phosphoproteins, milk casein, vitelline, lavitellenine and phosvitin from egg yolk may be used.
Parmi les glycoprotéines, on choisira avantageusement l'ovalbumine de l'oeuf, la ribonucléase et désoxyribonucléase, les mucines, l'orosomucoNde, les glycoprotéines et peptidoglycanes des membranes des bactéries, tels que la muréine et les muropeptides, la fétuine du sérum de veau. Among the glycoproteins, the ovalbumin of the egg, the ribonuclease and deoxyribonuclease, the mucins, the orosomuconde, the glycoproteins and peptidoglycans of the membranes of bacteria, such as murineptides and muropeptides, fetuine of calf serum, will advantageously be chosen. .
De même, on pourra utiliser divers sphingocéramides. Likewise, various sphingoceramides may be used.
En outre, parmi les lipoprotéines, on pourra utiliser avantageusement l'ou ss lipoprotéine du sérum, la lipovitelline et la lipovitellénine du jaune d'oeuf, la chlorôplastine des feuilles. In addition, among the lipoproteins, it is possible to use advantageously the seroprotein lipoprotein, lipovitellin and lipovitellenin from egg yolk, chloroplastin from the leaves.
La présente invention couvre également, selon un second aspect, les compositions pharmaceutiques, notamment dermatologiques et/ou cosmétiques préparées à partir d'une composition telle que précédemment défihie. The present invention also covers, according to a second aspect, pharmaceutical compositions, in particular dermatological and / or cosmetic compositions prepared from a composition as defined above.
Avantageusement, la proportion des principes actifs utilisés, comprenant la ou les substances azotées précitées, est de 0,01 à 20 % en poids, avantageusement de 0,01 à environ 10 % en poids par rapport au poids de la composition totale. Advantageously, the proportion of the active principles used, comprising the abovementioned nitrogenous substance or substances, is from 0.01 to 20% by weight, advantageously from 0.01 to about 10% by weight relative to the weight of the total composition.
Ces çompositions pourront être formulées sous forme de gel, de crème, de lait, de baume, de lotion, de manière à présenter une activité hydratante, nourrissante, régénératrice, stimulante de la croissance des cellules épidermiques, dermiques, du bulbe pileux, ou encore protectrice. These compositions can be formulated in the form of a gel, cream, milk, balm or lotion, so as to have a hydrating, nourishing, regenerative activity, stimulating the growth of epidermal cells, dermis, of the hair bulb, or else protective.
Selon une autre caractéristique avantageuse de l'invention, les principes actifs précités sont au moins en partie incorporés dans des phases lamellaires lipidiques hydratées ou dans des vésicules type liposome, notamment à une proportion de 10 à 60 %, encore mieux de 20 à 50 %, en poids des vésicules ou des phases lamellaires lipidiques par rapport à la composition totale. According to another advantageous characteristic of the invention, the abovementioned active principles are at least partly incorporated in hydrated lipidic lamellar phases or in liposome-type vesicles, in particular in a proportion of 10 to 60%, even better of 20 to 50%. , by weight of the vesicles or of the lipid lamellar phases relative to the total composition.
Les aminoacides selon l'invention, utilisés sous forme libre, seuls ou combinés entre eux, tout en étant ainsi engagés dans des liaisons peptidiques en formant des oligopeptides, polypeptides ou des protéines, procurent les activités suivantes - un confort cutané, - un effet hydratant, - un effet nutritif sur les cellules épidermiques et dermiques, - un effet modulateur sur l'activité cellulaire (stimulation de la
croissance, allongement de la durée de survie, une augmentation
des sécrétions et production cellulaire), - un effet protecteur cellulaire, - un effet réparateur ou régénérateur.The amino acids according to the invention, used in free form, alone or combined with one another, while thus being engaged in peptide bonds by forming oligopeptides, polypeptides or proteins, provide the following activities - skin comfort, - a moisturizing effect , - a nutritive effect on epidermal and dermal cells, - a modulating effect on cellular activity (stimulation of
growth, longer survival, increased
secretions and cell production), - a cellular protective effect, - a repairing or regenerating effect.
On obtient ainsi une stimulation de la croissance des kératînocytes épidermiques, du bulbe pileux, des fibroblastes dermiques ainsi que sur la production de leurs métabolites, des enzymes, des hormones, des energènes, des produits de sécrétion, d'excrétion. This stimulates the growth of epidermal keratinocytes, the hair bulb, dermal fibroblasts, as well as the production of their metabolites, enzymes, hormones, energens, secretion and excretion products.
Des compositions actuellement préférées sont données dans les exemples suivants donnés à titre d'illustration de l'invention, sans en limiter la portée. Ces exemples font tous partie intégrante de l'invention. Dans les exemples, les formulations de compositions sont des formulations centésimales données en poids, qui correspondent donc également à des pourcentages en poids. Presently preferred compositions are given in the following examples given by way of illustration of the invention, without limiting its scope. These examples are all an integral part of the invention. In the examples, the composition formulations are percentage formulations given by weight, which therefore also correspond to percentages by weight.
Dans les exemples suivants, les phases A et B sont chauffées à 800C environ séparément, puis sont mélangées et émulsionnées sous agitation turbine. L'émulsion obtenue est refroidie, puis les phases restantes sont incorporées. In the following examples, phases A and B are heated to approximately 800C separately, then are mixed and emulsified with turbine stirring. The emulsion obtained is cooled, then the remaining phases are incorporated.
Exemple 1 : Crème anti-vieillissement
Phase A : PLASMA HYDROLYSE 10,00
GLUTATHION REDUIT 0,15
CARNOSINE 0,10
METHYLPARABEN 0,20
EAU DISTILLEE 49,40
Phase B : MYRISTATE d'ISOPROPYLE 25,00
GLYCERYL STEARATE A.E. 10,00
LANOLINE 5,00
Phase C : PARFUM 0,15
Exemple 2 : Crème anti-rides
Phase A : ELASTINE NATIVE 1,00
COLLAGENE NATIF 0,50
L-CYSTEINE 0,50
ACIDE GLUTAMIQUE 1,00
L-LYSINE 0,80
OH-PROLINE 0,80
HYDROLYSAT de CASEINE 1,00
METHYLPARABEN 0,20
EAU DISTILLEE 72,55
Phase B : MYRISTATE d'ISOPROPYLE 10,00
HUILE de PARAFFINE 3,00
LANOLINE 5,00
ALCOOL CETOSTEARYLIQUE 1,00
TRIETHANOLAMINE STEARATE 2,50
Phase C : PARFUM 0,15
Exemple 3 : Crème nutritive
Phase A :HYDROLYSAT de KERATINE 0,50
HYDROLYSAT DE PLASMA 1,00
VITELLINE 0,80
ALBUMINE 1,00
L-ALANINE 0,25
L-GLYCINE 0,25
L-LYSINE 0,25
PROPYLENE GLYCOL 5,00
METHYLPARABEN 0,20
EAU DISTILLEE 68,75
Phase B : MYRISTATE d'ISOPROPYLE 15,00
LANOLINE 2,00
GLYCERYL STEARATE 3,00
ALCOOL CETOSTEARYLIQUE 2,00
Exemple 4 : Lotion anti-chute des cheveux
Phase A : HYDROLYSAT de PLASMA 10,00
HYDROLYSAT de KERATINE 3,00
LIQUIDE AMNIOTIQUE 10,00
GLYCERINE 5,00
METHYLPARABEN 0,20
PARFUM 0,15
EAU DISTILLEE qsp 100,00
Exemple 5 : Crème hydratante
Phase A : ACIDE PYRROLIDONE-CARBOXYLIQUE 1,00
UREE 1,00
EXTRAIT PLACENTAIRE 1,20
LIQUIDE AMNIOTIQUE 0,50
METHYLPARABEN 0,20
EAU DISTILLEE 30,95
Phase B :MYRISTATE d'ISOPROPYLE 40,00
LANOLINE 5,00
OLEATE de SORBITAN 3,00
CIRE de CARNAUBA 15,00
HUILE de PARAFFINE 1,00
CHOLESTEROL 1,00
Phase C : PARFUM 0,15
Exemple 6 : Crème contre le vieillissement cutané
Phase A : MANNITOL 0,60
GLYCOGENE 0,10
METHIONINE 0,10
ACIDE DESOXYRIBONUCLEIQUE 0,50
PROPYLENE GLYCOL 5,00
METHYLPARABEN 0,20
PEG 100 STEARATE 5,00
EAU DISTILLEE 73,35
Phase B : MYRISTATE d'ISOPROPYLE 10,00
HUILE de COCO HYDROGENEE 2,00
TRIETHANOLAMINE STEARATE 3,00
Phase C : PARFUM 0,15
Exemple 7 : Baume anti-rides
Phase A : SERUM ALBUMINE 10,00
LIPOPROTEINES 1,00
FIBRONECTINE 0,50
EXTRAITS ENRICHIS de
FLAVONOIDES 2,00
ACIDE HYALURONIQUE 0,30
PROPYLENE GLYCOL 5,00
PEG 1500 1,00
METHYLPARABEN 0,20
EAU DISTILLEE 77,85
Phase B : LANOLINE ETHOXYLEE 0,50
Phase C :XANTHANE GOMME 1,50
Phase D : PARFUM 0,15
Exemple 8 : Crème hydratante
Phase A : LIQUIDE AMNIOTIQUE 2,000
SORBITOL 1,000
PYROGLUTAMATE de Na 1,000
SACCHAROSE 0,500
DEXTROSE 0,500
LACTOSE 0,500
ACIDE GLUTAMIQUE 0,300
TRYPTOPHANE 0,500
UREE 0,125
PROPYLENE GLYCOL 2,000
METHYLPARABEN 0,200
EAU DISTILLEE 73,225
Phase B : MYRISTATE d'ISOPROPYLE 10,000
HUILE de PARAFFINE 2,000
LANOLINE 1,000
ALCOOL CETYLIQUE 3,000
STEARATE DE GLYCEROL A.E. 2,000
Phase C : PARFUM 0,150
Exemple 9 : Creme nourrissante
Phase A : CHONDROITINE SULFATE 1,00
ACIDE HYALURONIQUE 0,50
BETAINE 0,50
EXTRAITS BILIAIRES 0,20
L-LYSINE 0,50
METHYLPARABEN 0,20
EAU DISTILLEE 68,60
PROPYLENE GLYCOL 3,00
Phase B : LANOLINE 6,00
ACIDE STEARIQUE 3,00
HUILE de PARAFFINE 3,50
STEARATE de GLYCEROL 6,00
TRIETHANOLAMINE STEARATE 3,00
ALCOOL CETYLIQUE 4,00
Exemple 10 :Crème stimulante et protectrice
Phase A : ADN 2,00
MANNITOL 2,00
LIQUIDE AMNIOTIQUE 0,50
PROPYLENE GLYCOL 3,00
METHYLPARABEN 0,20
EAU DISTILLEE 62,15
Phase B : STEARATE de GLYCEROL A.E. 10,00
MYRISTATE d'ISOPROPYL 20,00 Phrase C : PARFUM 0,15
Dans tous les exemples 1 à 10, on pourra ajouter aux composants azotés une ou plusieurs molécules de nature glucidique.EXAMPLE 1 Anti-Aging Cream
Phase A: PLASMA HYDROLYSIS 10.00
REDUCED GLUTATHIONE 0.15
CARNOSINE 0.10
METHYLPARABEN 0.20
DISTILLED WATER 49.40
Phase B: ISOPROPYLE MYRISTATE 25.00
GLYCERYL STEARATE AE 10.00
LANOLINE 5.00
Phase C: PERFUME 0.15
EXAMPLE 2 Anti-Wrinkle Cream
Phase A: NATIVE ELASTINE 1.00
NATIVE COLLAGEN 0.50
L-CYSTEINE 0.50
GLUTAMIC ACID 1.00
L-LYSINE 0.80
OH-PROLINE 0.80
CASEIN HYDROLYSAT 1.00
METHYLPARABEN 0.20
DISTILLED WATER 72.55
Phase B: ISOPROPYLE MYRISTATE 10.00
PARAFFIN OIL 3.00
LANOLINE 5.00
CETOSTEARYL ALCOHOL 1.00
TRIETHANOLAMINE STEARATE 2.50
Phase C: PERFUME 0.15
Example 3: Nutritional cream
Phase A: HYDROLYSAT of KERATINE 0.50
PLASMA HYDROLYSAT 1.00
VITELLINE 0.80
ALBUMIN 1.00
0.25 L-ALANINE
L-GLYCINE 0.25
L-LYSINE 0.25
PROPYLENE GLYCOL 5.00
METHYLPARABEN 0.20
DISTILLED WATER 68.75
Phase B: ISOPROPYLE MYRISTATE 15.00
LANOLINE 2.00
GLYCERYL STEARATE 3.00
CETOSTEARYLIC ALCOHOL 2.00
EXAMPLE 4 Anti-Hair Loss Lotion
Phase A: PLASMA HYDROLYSAT 10.00
KERATINE HYDROLYSAT 3.00
AMNIOTIC LIQUID 10.00
GLYCERINE 5.00
METHYLPARABEN 0.20
PERFUME 0.15
DISTILLED WATER qs 100.00
EXAMPLE 5 Moisturizing Cream
Phase A: PYRROLIDONE-CARBOXYLIC ACID 1.00
UREE 1.00
PLACENTAL EXTRACT 1.20
AMNIOTIC LIQUID 0.50
METHYLPARABEN 0.20
DISTILLED WATER 30.95
Phase B: ISOPROPYLE MYRISTATE 40.00
LANOLINE 5.00
SORBITAN OLEATE 3.00
CARNAUBA WAX 15.00
PARAFFIN OIL 1.00
CHOLESTEROL 1.00
Phase C: PERFUME 0.15
EXAMPLE 6 Cream Against Skin Aging
Phase A: MANNITOL 0.60
GLYCOGENE 0.10
METHIONINE 0.10
DEOXYRIBONUCLEIC ACID 0.50
PROPYLENE GLYCOL 5.00
METHYLPARABEN 0.20
PEG 100 STEARATE 5.00
DISTILLED WATER 73.35
Phase B: ISOPROPYLE MYRISTATE 10.00
HYDROGENATED COCONUT OIL 2.00
TRIETHANOLAMINE STEARATE 3.00
Phase C: PERFUME 0.15
EXAMPLE 7 Anti-Wrinkle Balm
Phase A: ALBUMIN SERUM 10.00
LIPOPROTEINS 1.00
FIBRONECTIN 0.50
ENRICHED EXTRACTS from
FLAVONOIDS 2.00
HYALURONIC ACID 0.30
PROPYLENE GLYCOL 5.00
PEG 1500 1.00
METHYLPARABEN 0.20
DISTILLED WATER 77.85
Phase B: LANOLINE ETHOXYLATED 0.50
Phase C: XANTHANE GUM 1.50
Phase D: PERFUME 0.15
EXAMPLE 8 Moisturizing Cream
Phase A: AMNIOTIC LIQUID 2,000
SORBITOL 1,000
PYROGLUTAMATE from Na 1,000
SACCHAROSE 0,500
DEXTROSE 0.500
LACTOSE 0.500
GLUTAMIC ACID 0.300
TRYPTOPHANE 0.500
UREE 0.125
PROPYLENE GLYCOL 2,000
METHYLPARABEN 0.200
DISTILLED WATER 73,225
Phase B: ISOPROPYLE 10,000 MYRISTATE
PARAFFIN OIL 2,000
LANOLINE 1,000
CETYL ALCOHOL 3,000
GLYCEROL AE 2,000 STEARATE
Phase C: PERFUME 0.150
EXAMPLE 9 Nourishing Cream
Phase A: CHONDROITINE SULFATE 1.00
HYALURONIC ACID 0.50
BETA 0.50
BILARIAL EXTRACTS 0.20
L-LYSINE 0.50
METHYLPARABEN 0.20
DISTILLED WATER 68.60
PROPYLENE GLYCOL 3.00
Phase B: LANOLINE 6.00
STEARIC ACID 3.00
PARAFFIN OIL 3.50
GLARCEROL STEARATE 6.00
TRIETHANOLAMINE STEARATE 3.00
CETYL ALCOHOL 4.00
EXAMPLE 10 Stimulating and Protective Cream
Phase A: DNA 2.00
MANNITOL 2.00
AMNIOTIC LIQUID 0.50
PROPYLENE GLYCOL 3.00
METHYLPARABEN 0.20
DISTILLED WATER 62.15
Phase B: STEARATE from GLYCEROL AE 10.00
ISOPROPYL MYRISTATE 20.00 Phrase C: PERFUME 0.15
In all of the examples 1 to 10, one or more carbohydrate molecules may be added to the nitrogen components.
Par ailleurs, les compositions selon l'invention peuvent être formulées de telle sorte qu'au moins une partie des principes actifs soit incorporée dans des phases lamellaires lipidiques hydratées ou dans des vésicules type liposome. Furthermore, the compositions according to the invention can be formulated so that at least a portion of the active ingredients is incorporated into hydrated lipid lamellar phases or into liposome-type vesicles.
Pour ce faire, la composition sera préparée selon la technique suivante
Les principes actifs sont tout d'abord préparés sous forme d'une solution aqueuse.To do this, the composition will be prepared according to the following technique
The active ingredients are first prepared in the form of an aqueous solution.
Les phases lamellaires lipidiques ou les vésicules des liposomes seront constituées d'au moins une substance suivante, constituant une phase lipidique. The lipid lamellar phases or the liposome vesicles will consist of at least one of the following substances, constituting a lipid phase.
- les phospholipides, d'origine naturelle ou synthétique, - les phospholipides associés à des glycérides, - les phospholipides associés à des glycolipides, - les cérébrosides, - les sphingolipides, - les céphalines, - les phosphoaminolipides, - les cérébroglucosides, - les gangliosides, - éventuellement combinés à du cholestérol, naturel ou synthétique.- phospholipids, of natural or synthetic origin, - phospholipids associated with glycerides, - phospholipids associated with glycolipids, - cerebrosides, - sphingolipids, - cephalins, - phosphoaminolipids, - cerebroglucosides, - gangliosides , - possibly combined with cholesterol, natural or synthetic.
Cette phase lipidique est tout d'abord dissoute dans un solvant volatil, variant selon le type de phospholipides ou sphingolipides choisi, par exemple un solvant organique tel que le chloroforme, le méthanol. This lipid phase is first dissolved in a volatile solvent, varying according to the type of phospholipids or sphingolipids chosen, for example an organic solvent such as chloroform, methanol.
La solution lipidique obtenue est placée dans un ballon puis évaporée sous pression réduite dans un évaporateur rotatif, jusqu' formation d'un film sur les parois du ballon. The lipid solution obtained is placed in a flask and then evaporated under reduced pressure in a rotary evaporator, until a film is formed on the walls of the flask.
Puis on ajoute, sous agitation constante, la solution aqueuse des principes actifs à encapsuler, ce qui permet d'obtenir une suspension. Then the aqueous solution of the active ingredients to be encapsulated is added, with constant stirring, which makes it possible to obtain a suspension.
La suspension obtenue est passée aux ultrasons. The suspension obtained is passed to ultrasound.
On obtient ainsi une suspension de vésicules type liposome incorporant au moins en partie les principes actifs en solution aqueuse. A suspension of liposome-type vesicles is thus obtained, incorporating at least part of the active principles in aqueous solution.
L'encapsulation des principes actifs ainsi réalisée entraîne une optimisation de leur activité cosmétodynamique. The encapsulation of the active ingredients thus produced leads to an optimization of their cosmetodynamic activity.
Les exemples suivants concernent ainsi des compositions dites liposomées obtenues selon cette technique. The following examples thus relate to so-called liposomal compositions obtained according to this technique.
Exemple 11 : Composition liposomée - Phase lipidique :
PHOSPHOLIPIDES 90
. CHOLESTEROL 10 - Phase active aqueuse
. PLASMA HYDROLYSE 10,00
. GLUTATHION 0,15
. CARNOSINE 1,00
. METHYLPARABEN 0,20
. EAU DISTILLEE qsp 100,00
La préparation est réalisée selon la technique ci-dessus décrite.Example 11: Liposomal composition - Lipid phase:
PHOSPHOLIPIDS 90
. CHOLESTEROL 10 - Active aqueous phase
. PLASMA HYDROLYSIS 10.00
. GLUTATHION 0.15
. CARNOSINE 1.00
. METHYLPARABEN 0.20
. DISTILLED WATER qs 100.00
The preparation is carried out according to the technique described above.
Exemple 12 : Composition liposomée - Phase lipidique
. SPHINGOLIPIDES 90
CHOLESTEROL 10 - Phase active aqueuse
. TYROSINE 0,30
. ARGININE 0,30
. METHYLPARABEN 0,10
. EAU DISTILLEE qsp 100,00
La préparation est réalisée selon la technique ci-dessus décrite.Example 12: Liposomal Composition - Lipid Phase
. SPHINGOLIPIDS 90
CHOLESTEROL 10 - Active aqueous phase
. TYROSINE 0.30
. ARGININE 0.30
. METHYLPARABEN 0.10
. DISTILLED WATER qs 100.00
The preparation is carried out according to the technique described above.
Exemple 13 : Composition liposomée - Phase lipidique :
PHOSPHOLIPIDES 90
. CHOLESTEROL 10 - Phase active aqueuse
. ELASTINE NATIVE 1,00
. COLLAGENE NATIF 0,50
. L-CYSTEINE 0,50
. ACIDE GLUTAMIQUE 1,00
. L-LYSINE 0,80
. OH-PROLINE 0,80
. HYDROLYSAT de LAIT 1,00
. METHYLPARABEN 0,15
. EAU DISTILLEE qsp 100,00
La préparation est réalisée selon la technique ci-dessus exposée.Example 13: Liposomal composition - Lipid phase:
PHOSPHOLIPIDS 90
. CHOLESTEROL 10 - Active aqueous phase
. NATIVE ELASTINE 1.00
. NATIVE COLLAGEN 0.50
. L-CYSTEINE 0.50
. GLUTAMIC ACID 1.00
. L-LYSINE 0.80
. OH-PROLINE 0.80
. MILK HYDROLYSAT 1.00
. METHYLPARABEN 0.15
. DISTILLED WATER qs 100.00
The preparation is carried out according to the technique described above.
Exemple 14 : Composition liposomée - Phase lipidique
. CEREBROSIDES 90
CHOLESTEROL 10 - Phase active aqueuse
. HYDROLYSAT de PLASMA 0,50
. GLYCOPROTEINES du PLASMA 1,00
. VITELLINE 0,80
. ALBUMINE 1,00
. L-ALANINE 0,25
. UREE 0,70
. METHYLPARABEN 0,10
. EAU DISTILLEE qsp 100,00
La préparation de la composition liposomée est réalisée selon la technique ci-dessus décrite.EXAMPLE 14 Liposomal Composition - Lipid Phase
. CEREBROSIDES 90
CHOLESTEROL 10 - Active aqueous phase
. PLASMA HYDROLYSAT 0.50
. PLASMA GLYCOPROTEINS 1.00
. VITELLINE 0.80
. ALBUMIN 1.00
. 0.25 L-ALANINE
. UREE 0.70
. METHYLPARABEN 0.10
. DISTILLED WATER qs 100.00
The preparation of the liposomal composition is carried out according to the technique described above.
Exemple 15 : Composition liposomée - Phase lipidique
PHOSPHOLIPIDES 90
. CHOLESTEROL 10 - Phase active aqueuse
HYDROLYSAT de PLACENTA 10,00
. HYDROLYSAT de KERATINE 3,00
. LIQUIDE AMNIOTIQUE 10,00
. METHYLPARABEN 0,20
. EAU DISTILLEE qsp 100,00
La préparation de cette composition liposomée est réalisée selon la technique ci-dessus décrite.EXAMPLE 15 Liposomal Composition - Lipid Phase
PHOSPHOLIPIDS 90
. CHOLESTEROL 10 - Active aqueous phase
PLACENTA HYDROLYSAT 10.00
. KERATINE HYDROLYSAT 3.00
. AMNIOTIC LIQUID 10.00
. METHYLPARABEN 0.20
. DISTILLED WATER qs 100.00
The preparation of this liposomal composition is carried out according to the technique described above.
Exemple 16 : Composition liposomée - Phase lipidique :
PHOSPHOLIPIDES 90
. CHOLESTEROL 10 - Phase active aqueuse
. ACIDE PYRROLIDONE CARBOXYLIQUE 1,00
. UREE 1,00
. EXTRAIT de THYMUS 10,00
. METHYLPARABEN 0,20
. EAU DISTILLEE qsp 100,00
On prépare cette composition de la même manière que pour les exemples précédents 11 à 15. Example 16: Liposomal composition - Lipid phase:
PHOSPHOLIPIDS 90
. CHOLESTEROL 10 - Active aqueous phase
. PYRROLIDONE CARBOXYLIC ACID 1.00
. UREE 1.00
. THYMUS EXCERPT 10.00
. METHYLPARABEN 0.20
. DISTILLED WATER qs 100.00
This composition is prepared in the same way as for the previous examples 11 to 15.
Exemple 17 : Composition liposomée - Phase lipidique
. PHOSPHOLIPIDES 90
. CHOLESTEROL 10 - Phase active aqueuse
. MANNITOL 0,10
. LEUCINE 0,10
. PROLINE 0,40
. GLYCINE 0,40
. L-CYSTEINE 0,10
. L-METHIONINE 0,10
. ACIDE DESOXYRIBONUCLEIQUE 0,50
. METHYLPARABEN 0,20
. EAU DISTILLEE qsp 100,00
Cette composition est préparée comme décrit pour les exemples 11 à 16.EXAMPLE 17 Liposomal Composition - Lipid Phase
. PHOSPHOLIPIDS 90
. CHOLESTEROL 10 - Active aqueous phase
. MANNITOL 0.10
. LEUCINE 0.10
. PROLINE 0.40
. GLYCINE 0.40
. L-CYSTEINE 0.10
. L-METHIONINE 0.10
. DEOXYRIBONUCLEIC ACID 0.50
. METHYLPARABEN 0.20
. DISTILLED WATER qs 100.00
This composition is prepared as described for Examples 11 to 16.
Exemple 18 : Composition liposomée - Phase lipidique
. PHOSPHOLIPIDES 90
. CHOLESTEROL 10 - Phase active aqueuse
. HYDROLYSAT de LEVURE 10,00
. FIBRONECTINE 0,50
. GLYCOGENE 5,00
. GLYCOLYSAT de FUCUS 2,00
. ACIDE HYALURONIQUE, Na sel 0,10
. METHYLPARABEN 0,20
. EAU DISTILLEE qsp 1O0,J
On prépare cette composition liposomée comme pour les exemples précédents 11 à 17.EXAMPLE 18 Liposomal Composition - Lipid Phase
. PHOSPHOLIPIDS 90
. CHOLESTEROL 10 - Active aqueous phase
. YEAST HYDROLYSAT 10.00
. FIBRONECTIN 0.50
. GLYCOGEN 5.00
. FUCUS GLYCOLYSAT 2.00
. HYALURONIC ACID, Na salt 0.10
. METHYLPARABEN 0.20
. DISTILLED WATER qs 1O0, J
This liposomal composition is prepared as in the previous examples 11 to 17.
Exemple 19 : Composition liposomée - Phase lipidique
. PHOSPHOLIPIDES 90
CHOLESTEROL 10 - Phase active aqueuse
. LIQUIDE AMNIOTIQUE 10,00
. SORBITOL 1,00
BETAINE 0,50
. EXTRAIT d'OVAIRE 10,00
. LAIT HYDROLYSE 5,00
. FRUCTOSE 2,00
. ETHANOLAMINE 0,30
ORNITHINE 0,90
. METHYLPARABEN 0,20
. EAU DISTILLEE qsp 100,00
On prépare cette composition liposomée comme pour les exemples précédents 11 à 18.EXAMPLE 19 Liposomal Composition - Lipid Phase
. PHOSPHOLIPIDS 90
CHOLESTEROL 10 - Active aqueous phase
. AMNIOTIC LIQUID 10.00
. SORBITOL 1.00
BETA 0.50
. Ovarian extract 10.00
. HYDROLYSIS MILK 5.00
. FRUCTOSE 2.00
. ETHANOLAMINE 0.30
ORNITHINE 0.90
. METHYLPARABEN 0.20
. DISTILLED WATER qs 100.00
This liposomal composition is prepared as in the previous examples 11 to 18.
Exemple 20 : Composition liposomée - Phase lipidique
PHOSPHOLIPIDES 90
. CHOLESTEROL 10 - Phase active aqueuse
. CHONDROITINE SULFATE 1,00
. ACIDE HYALURONIQUE, Na 2,00
. BETAINE 0,50
EXTRAITS BILIAIRES 0,20
. ACIDE PYRUVIQUE 0,20
. METHYLPARABEN 0,20
. EAU DISTILLEE qsp 100,00
On prépare cette composition liposomée comme pour les exemples précédents Il à 19. EXAMPLE 20 Liposomal Composition - Lipid Phase
PHOSPHOLIPIDS 90
. CHOLESTEROL 10 - Active aqueous phase
. CHONDROITINE SULFATE 1.00
. HYALURONIC ACID, Na 2.00
. BETA 0.50
BILARIAL EXTRACTS 0.20
. PYRUVIC ACID 0.20
. METHYLPARABEN 0.20
. DISTILLED WATER qs 100.00
This liposomal composition is prepared as for the previous examples II to 19.
Exemple 21 : Composition liposomée - Phase lipidique
. SPHINGOLIPIDES 95
. CHOLESTEROL 5 - Phase active aqueuse
. ADN 2,00
GLYCOGENE 2,00
. LIQUIDE AMNIOTIQUE 0,50
. METHYLPARABEN 0,20
. EAU DISTILLEE qsp 100,00
On prépare cette composition liposomée comme pour les exemples précédents 11 à 20.EXAMPLE 21 Liposomal Composition - Lipid Phase
. SPHINGOLIPIDS 95
. CHOLESTEROL 5 - Aqueous active phase
. DNA 2.00
GLYCOGEN 2.00
. AMNIOTIC LIQUID 0.50
. METHYLPARABEN 0.20
. DISTILLED WATER qs 100.00
This liposomal composition is prepared as in the previous examples 11 to 20.
Ces compositions faisant l'objet des exemples 1 à 21 pourront être utilisées telles quelles comme compositions pharmaceutiques, notamment dermatologiques et/ou cosmétiques, ou pourront être utilisées comme matière de base pour la formulation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmétiques. These compositions which are the subject of Examples 1 to 21 could be used as such as pharmaceutical compositions, in particular dermatological and / or cosmetic, or could be used as base material for the formulation of pharmaceutical compositions, especially dermatological and / or cosmetic.
Pour ce faire, on pourra incorporer d'autres principes actifs ou des véhicules excipients habituels. Par exemple, on pourra gélifier ces compositions, ce qui est avantageux pour la stabilité des vésicules. To do this, it is possible to incorporate other active ingredients or usual excipient vehicles. For example, these compositions can be gelled, which is advantageous for the stability of the vesicles.
Dans la composition terminée, la phase lipidique de la composition liposomée peut constituer de 10 à 60 %, de préférence de 20 à 60 % de la composition totale. In the finished composition, the lipid phase of the liposomal composition can constitute from 10 to 60%, preferably from 20 to 60% of the total composition.
Avec les compositions de l'invention, notamment les compositions 1 à 21 ci-dessus décrites, on obtient une activité supérieure principalement en ce qui concerne l'activité hydratante par reconstitution du NMF (Natural Moisturing Factor), nourrissante, régénératrice tissulaire, stimulante de la croissance des cellules épidermiques, dermiques, du bulbe pileux, et une accélération du bronzage. With the compositions of the invention, in particular compositions 1 to 21 described above, a higher activity is obtained mainly with regard to the hydrating activity by reconstitution of the NMF (Natural Moisturing Factor), nourishing, regenerating tissue, stimulating the growth of epidermal and dermal cells, of the hair bulb, and an acceleration of tanning.
Les compositions selon l'invention pourront contenir d'autres principes actifs et notamment ceux de nature glucidique (osique, osidique, hétérosidique), d'origine naturelle ou synthétique. The compositions according to the invention may contain other active principles and in particular those of a carbohydrate nature (osic, osidic, heterosidic), of natural or synthetic origin.
L'invention comprend donc tous les moyens constituants des équivalents techniques des moyens décrits ainsi que leur diverses combinaisons. The invention therefore includes all the means constituting the technical equivalents of the means described as well as their various combinations.
Claims (9)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8802164A FR2609393A1 (en) | 1988-02-23 | 1988-02-23 | Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared |
| FR8901439A FR2627385B3 (en) | 1988-02-23 | 1989-02-03 | COMPOSITION ESPECIALLY USEFUL AS A BASE MATERIAL FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, ESPECIALLY DERMATOLOGICAL AND / OR COSMETIC |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8802164A FR2609393A1 (en) | 1988-02-23 | 1988-02-23 | Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2609393A1 true FR2609393A1 (en) | 1988-07-15 |
Family
ID=9363522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8802164A Pending FR2609393A1 (en) | 1988-02-23 | 1988-02-23 | Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2609393A1 (en) |
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2616659A1 (en) * | 1987-06-16 | 1988-12-23 | Sederma Sa | Method for promoting the penetration of macromolecules through the epidermis, used for the production of cosmetic preparations |
| FR2624374A1 (en) * | 1987-12-09 | 1989-06-16 | Induchem Ag | PREPARATION, IN PARTICULAR ANTISOLAR COSMETICS, AND METHOD FOR PASSING AN ACTIVE SUBSTANCE INTO THE SKIN |
| EP0346189A1 (en) * | 1988-06-03 | 1989-12-13 | Pierre Fabre Cosmetique | Dermato-cosmetic composition for the treatment of skin aging and for the prevention of wrinkles |
| EP0365868A2 (en) * | 1988-10-28 | 1990-05-02 | Societe Des Produits Nestle S.A. | Process to separate glycolipides from a mixture of lipids, and use of the fractions obtained |
| WO1990012565A1 (en) * | 1989-04-25 | 1990-11-01 | Nattermann, A. & Cie. Gmbh | Water-containing formulations with phospholipids |
| FR2647342A1 (en) * | 1989-05-23 | 1990-11-30 | Sanofi Sa | COSMETIC COMPOSITION OPPOSING SKIN AGING |
| EP0412947A1 (en) * | 1989-08-08 | 1991-02-13 | POLIFARMA S.p.A. | Cosmetic use of 3-indolepyruvic acid |
| FR2651434A1 (en) * | 1989-09-07 | 1991-03-08 | Grinos Ind Farmacobiologic | Composition of depolymerised deoxyribonucleic acids for local use in cosmetic treatments of the skin and body |
| FR2653014A1 (en) * | 1989-10-17 | 1991-04-19 | Roussel Uclaf | USE OF GLYCOPROTEINS EXTRACTED FROM BACTERIA GRAM (-) FOR THE MANUFACTURE OF COSMETIC OR DERMATOLOGICAL COMPOSITIONS AND COMPOSITIONS COMPRISING THE SAME. |
| EP0436611A1 (en) * | 1988-09-28 | 1991-07-17 | Commonwealth Scientific And Industrial Research Organisation | Compound and method for the retardation of collagen cross-linking |
| EP0462964A1 (en) * | 1989-03-13 | 1992-01-02 | Cellegy Pharmaceuticals, Inc. | Treatment of skin diseases and tumors |
| WO1992000720A1 (en) * | 1990-07-12 | 1992-01-23 | Schmidt Achert Martin | Agent and process for stimulating growth and regeneration of hair and nails |
| FR2668063A1 (en) * | 1990-10-17 | 1992-04-24 | Fabre Pierre Cosmetique | LIPOSOMES OF THERMAL WATER STABILIZED IN A DNA GEL. |
| FR2668365A1 (en) * | 1990-10-25 | 1992-04-30 | Sederma Sa | Use in cosmetics of N-acetyl peptides endowed with biological activity |
| EP0490581A1 (en) * | 1990-12-07 | 1992-06-17 | Unilever Plc | Cosmetic composition |
| DE4205931A1 (en) * | 1992-02-20 | 1993-08-26 | Maindok Friedrich | Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth |
| US5256649A (en) * | 1989-05-23 | 1993-10-26 | Elf Sanofi | Cosmetic composition against aging of the skin |
| DE4216667A1 (en) * | 1992-05-20 | 1993-11-25 | Wella Ag | Compsn. for treating hair - contains alpha-keto-di:carboxylic acid to remove residues of hydrogen peroxide |
| FR2704144A1 (en) * | 1993-04-23 | 1994-10-28 | Patrinove | Stimulation of keratinocytes with asc III to modulate fibroblasts |
| FR2704751A1 (en) * | 1993-05-07 | 1994-11-10 | Oreal | Composition based on fructose, glucose and cereal globular proteins or their hydrolysates to reduce hair loss and / or promote hair regrowth. |
| FR2706300A1 (en) * | 1993-06-17 | 1994-12-23 | Dior Christian Parfums | Use of a peptide having a lysine group and an alanine group in the terminal position for the preparation of a depigmenting composition and depigmenting composition comprising it. |
| FR2718028A1 (en) * | 1994-04-01 | 1995-10-06 | Sederma Sa | Skin or scalp care cosmetic or dermatological compsn. |
| FR2735022A1 (en) * | 1995-06-06 | 1996-12-13 | Sederma Sa | Cosmetics and dermo-pharmaceutical compsns contg peptide hydrolysates rich in glutamine |
| WO1997007772A1 (en) * | 1995-08-23 | 1997-03-06 | Quest International B.V. | Compositions containing a peptide cell growth promoter |
| WO1997019672A1 (en) * | 1995-11-29 | 1997-06-05 | Handelman, Joseph, H. | Reduction of hair growth |
| WO1997025023A1 (en) * | 1996-01-10 | 1997-07-17 | Guido Paduano | Skin treatment formulation and uses thereof |
| WO1997047276A1 (en) * | 1996-06-10 | 1997-12-18 | Bio-Scientific Limited | The use of l-lysine in the treatment of hair loss |
| EP0834301A1 (en) * | 1996-10-02 | 1998-04-08 | Boehringer Ingelheim Limited | Compositions comprising glutathione liposomes |
| FR2796550A1 (en) * | 1999-07-21 | 2001-01-26 | Asepta Lab | PREPARATIONS AND APPLICATIONS OF N-ACYLAMINOACID ESTERS |
| US6270791B1 (en) | 1999-06-11 | 2001-08-07 | Keraplast Technologies, Ltd. | Soluble keratin peptide |
| US6479059B2 (en) * | 1998-06-22 | 2002-11-12 | Gecomwert Anstalt | Trichological lotion for topical use |
| US6585987B1 (en) * | 1998-11-13 | 2003-07-01 | Continental Projects Limited | Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions |
| WO2006013082A1 (en) * | 2004-08-04 | 2006-02-09 | Vama Farmacosmetica S.R.L. | 1-carnitine-based cosmetic raw material for a preparation with long-lasting moisturising effect, and cosmetic preparation obtained with this raw material |
| KR100522381B1 (en) * | 1996-06-10 | 2006-02-17 | 바이오-사이언티픽 리미티드 | Use of L-Lysine in Hair Loss Treatment |
| EP1817006A2 (en) * | 2004-11-07 | 2007-08-15 | F. Timothy Guilford | Liposomal formulation for oral administration of glutathione (reduced) |
| US8349359B2 (en) | 2004-11-07 | 2013-01-08 | Your Energy Systems, LLC | Liposomal formulation for oral administration of glutathione (reduced) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2037160A (en) * | 1978-12-08 | 1980-07-09 | Dso Pharmachim | Milk-derived products |
| GB2052976A (en) * | 1979-05-29 | 1981-02-04 | Fresenius Chem Pharm Ind | Pharmaceutical preparation containing carnitine for lowering the lipid level in the body |
| EP0106309A2 (en) * | 1982-10-12 | 1984-04-25 | Kailash Kumar Dr. Prof. Gauri | Biologically active extracts, process for their manufacture, medicinal and cosmetical preparations comprising them, and their use as additives in foodstuffs and stimulants |
| EP0120722A1 (en) * | 1983-02-08 | 1984-10-03 | Parfums Christian Dior | Process for stimulating the multiplication of cells; cosmetic and pharmaceutical composition and a complementary composition for cellular cultures applying this process |
| EP0165123A2 (en) * | 1984-05-11 | 1985-12-18 | ANVAR Agence Nationale de Valorisation de la Recherche | Lipophile derivatives of muramyl peptides having macrophage-activating properties, compositions containing them and processes for obtaining them |
| EP0237398A1 (en) * | 1986-02-25 | 1987-09-16 | Lvmh Recherche | Use of biologically active polypeptides and compositions containing them |
-
1988
- 1988-02-23 FR FR8802164A patent/FR2609393A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2037160A (en) * | 1978-12-08 | 1980-07-09 | Dso Pharmachim | Milk-derived products |
| GB2052976A (en) * | 1979-05-29 | 1981-02-04 | Fresenius Chem Pharm Ind | Pharmaceutical preparation containing carnitine for lowering the lipid level in the body |
| EP0106309A2 (en) * | 1982-10-12 | 1984-04-25 | Kailash Kumar Dr. Prof. Gauri | Biologically active extracts, process for their manufacture, medicinal and cosmetical preparations comprising them, and their use as additives in foodstuffs and stimulants |
| EP0120722A1 (en) * | 1983-02-08 | 1984-10-03 | Parfums Christian Dior | Process for stimulating the multiplication of cells; cosmetic and pharmaceutical composition and a complementary composition for cellular cultures applying this process |
| EP0165123A2 (en) * | 1984-05-11 | 1985-12-18 | ANVAR Agence Nationale de Valorisation de la Recherche | Lipophile derivatives of muramyl peptides having macrophage-activating properties, compositions containing them and processes for obtaining them |
| EP0237398A1 (en) * | 1986-02-25 | 1987-09-16 | Lvmh Recherche | Use of biologically active polypeptides and compositions containing them |
Cited By (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2616659A1 (en) * | 1987-06-16 | 1988-12-23 | Sederma Sa | Method for promoting the penetration of macromolecules through the epidermis, used for the production of cosmetic preparations |
| FR2624374A1 (en) * | 1987-12-09 | 1989-06-16 | Induchem Ag | PREPARATION, IN PARTICULAR ANTISOLAR COSMETICS, AND METHOD FOR PASSING AN ACTIVE SUBSTANCE INTO THE SKIN |
| EP0346189A1 (en) * | 1988-06-03 | 1989-12-13 | Pierre Fabre Cosmetique | Dermato-cosmetic composition for the treatment of skin aging and for the prevention of wrinkles |
| EP0436611A4 (en) * | 1988-09-28 | 1992-03-11 | Peptide Technology Ltd | Compound and method for the retardation of collagen cross-linking |
| EP0436611A1 (en) * | 1988-09-28 | 1991-07-17 | Commonwealth Scientific And Industrial Research Organisation | Compound and method for the retardation of collagen cross-linking |
| EP0365868A2 (en) * | 1988-10-28 | 1990-05-02 | Societe Des Produits Nestle S.A. | Process to separate glycolipides from a mixture of lipids, and use of the fractions obtained |
| EP0365868A3 (en) * | 1988-10-28 | 1990-06-27 | Societe Des Produits Nestle S.A. | Process to separate glycolipides from a mixture of lipids, and use of the fractions obtained |
| EP0462964A1 (en) * | 1989-03-13 | 1992-01-02 | Cellegy Pharmaceuticals, Inc. | Treatment of skin diseases and tumors |
| EP0462964A4 (en) * | 1989-03-13 | 1993-02-10 | Carl Richard Thornfeldt | Treatment of skin diseases and tumors |
| WO1990012565A1 (en) * | 1989-04-25 | 1990-11-01 | Nattermann, A. & Cie. Gmbh | Water-containing formulations with phospholipids |
| FR2647342A1 (en) * | 1989-05-23 | 1990-11-30 | Sanofi Sa | COSMETIC COMPOSITION OPPOSING SKIN AGING |
| US5256649A (en) * | 1989-05-23 | 1993-10-26 | Elf Sanofi | Cosmetic composition against aging of the skin |
| EP0412947A1 (en) * | 1989-08-08 | 1991-02-13 | POLIFARMA S.p.A. | Cosmetic use of 3-indolepyruvic acid |
| FR2651434A1 (en) * | 1989-09-07 | 1991-03-08 | Grinos Ind Farmacobiologic | Composition of depolymerised deoxyribonucleic acids for local use in cosmetic treatments of the skin and body |
| EP0416677A1 (en) * | 1989-09-07 | 1991-03-13 | Crinos Industria Farmacobiologica S.p.A. | Compositions for topical cosmetic use containing depolymerized nucleic acids |
| GR900100612A (en) * | 1989-09-07 | 1992-01-20 | Crinos Ind Farmabiolog | Compositions for local use |
| BE1003350A3 (en) * | 1989-09-07 | 1992-03-03 | Crinos Industria Farmaco | DEPOLYMERIZED DEOXYRIBONUCLEIC ACID COMPOSITIONS FOR LOCAL USE IN COSMETIC SKIN AND BODY TREATMENTS. |
| BE1004601A3 (en) * | 1989-10-17 | 1992-12-22 | Roussel Uclaf | Use of bacteria extracted glycoproteins gram (-) for the manufacture of cosmetic or dermatological and composition containing. |
| FR2653014A1 (en) * | 1989-10-17 | 1991-04-19 | Roussel Uclaf | USE OF GLYCOPROTEINS EXTRACTED FROM BACTERIA GRAM (-) FOR THE MANUFACTURE OF COSMETIC OR DERMATOLOGICAL COMPOSITIONS AND COMPOSITIONS COMPRISING THE SAME. |
| AT403655B (en) * | 1989-10-17 | 1998-04-27 | Boots Co Plc | USE OF GLYCOPROTEINS FROM GRAM-NEGATIVE BACTERIA IN A METHOD FOR THE PRODUCTION OF COSMETIC OR DERMATOLOGICAL COMPOSITIONS PROMOTING HAIR GROWTH, AND SUCH COMPOSITIONS |
| WO1992000720A1 (en) * | 1990-07-12 | 1992-01-23 | Schmidt Achert Martin | Agent and process for stimulating growth and regeneration of hair and nails |
| WO1992006666A1 (en) * | 1990-10-17 | 1992-04-30 | Pierre Fabre Cosmetique | Dna gel stabilized thermal water liposomes |
| US5376379A (en) * | 1990-10-17 | 1994-12-27 | Pierre Fabre Cosmetique | Liposomes of thermal waters stabilized in a DNA gel |
| FR2668063A1 (en) * | 1990-10-17 | 1992-04-24 | Fabre Pierre Cosmetique | LIPOSOMES OF THERMAL WATER STABILIZED IN A DNA GEL. |
| FR2668365A1 (en) * | 1990-10-25 | 1992-04-30 | Sederma Sa | Use in cosmetics of N-acetyl peptides endowed with biological activity |
| EP0490581A1 (en) * | 1990-12-07 | 1992-06-17 | Unilever Plc | Cosmetic composition |
| DE4205931A1 (en) * | 1992-02-20 | 1993-08-26 | Maindok Friedrich | Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth |
| DE4216667A1 (en) * | 1992-05-20 | 1993-11-25 | Wella Ag | Compsn. for treating hair - contains alpha-keto-di:carboxylic acid to remove residues of hydrogen peroxide |
| FR2704144A1 (en) * | 1993-04-23 | 1994-10-28 | Patrinove | Stimulation of keratinocytes with asc III to modulate fibroblasts |
| WO1994026239A1 (en) * | 1993-05-07 | 1994-11-24 | L'oreal | Composition for reducing hair loss or stimulating hair growth |
| FR2704751A1 (en) * | 1993-05-07 | 1994-11-10 | Oreal | Composition based on fructose, glucose and cereal globular proteins or their hydrolysates to reduce hair loss and / or promote hair regrowth. |
| FR2706300A1 (en) * | 1993-06-17 | 1994-12-23 | Dior Christian Parfums | Use of a peptide having a lysine group and an alanine group in the terminal position for the preparation of a depigmenting composition and depigmenting composition comprising it. |
| WO1995000115A1 (en) * | 1993-06-17 | 1995-01-05 | Parfums Christian Dior | Utilization of a peptide having a lysin group and an alanine group in the terminal position for the preparation of a depigmenting composition, and depigmenting composition thus obtained |
| FR2718028A1 (en) * | 1994-04-01 | 1995-10-06 | Sederma Sa | Skin or scalp care cosmetic or dermatological compsn. |
| FR2735022A1 (en) * | 1995-06-06 | 1996-12-13 | Sederma Sa | Cosmetics and dermo-pharmaceutical compsns contg peptide hydrolysates rich in glutamine |
| WO1997007772A1 (en) * | 1995-08-23 | 1997-03-06 | Quest International B.V. | Compositions containing a peptide cell growth promoter |
| WO1997019672A1 (en) * | 1995-11-29 | 1997-06-05 | Handelman, Joseph, H. | Reduction of hair growth |
| US5728736A (en) * | 1995-11-29 | 1998-03-17 | Shander; Douglas | Reduction of hair growth |
| AU723723B2 (en) * | 1995-11-29 | 2000-09-07 | Gillette Company, The | Reduction of hair growth |
| WO1997025023A1 (en) * | 1996-01-10 | 1997-07-17 | Guido Paduano | Skin treatment formulation and uses thereof |
| WO1997047276A1 (en) * | 1996-06-10 | 1997-12-18 | Bio-Scientific Limited | The use of l-lysine in the treatment of hair loss |
| KR100522381B1 (en) * | 1996-06-10 | 2006-02-17 | 바이오-사이언티픽 리미티드 | Use of L-Lysine in Hair Loss Treatment |
| US6136860A (en) * | 1996-06-10 | 2000-10-24 | Bio-Scientific Limited | Use of L-lysine in the treatment of hair loss |
| EP0834301A1 (en) * | 1996-10-02 | 1998-04-08 | Boehringer Ingelheim Limited | Compositions comprising glutathione liposomes |
| US6479059B2 (en) * | 1998-06-22 | 2002-11-12 | Gecomwert Anstalt | Trichological lotion for topical use |
| US6585987B1 (en) * | 1998-11-13 | 2003-07-01 | Continental Projects Limited | Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions |
| US6270791B1 (en) | 1999-06-11 | 2001-08-07 | Keraplast Technologies, Ltd. | Soluble keratin peptide |
| FR2796550A1 (en) * | 1999-07-21 | 2001-01-26 | Asepta Lab | PREPARATIONS AND APPLICATIONS OF N-ACYLAMINOACID ESTERS |
| WO2006013082A1 (en) * | 2004-08-04 | 2006-02-09 | Vama Farmacosmetica S.R.L. | 1-carnitine-based cosmetic raw material for a preparation with long-lasting moisturising effect, and cosmetic preparation obtained with this raw material |
| EP1817006A2 (en) * | 2004-11-07 | 2007-08-15 | F. Timothy Guilford | Liposomal formulation for oral administration of glutathione (reduced) |
| EP1817006A4 (en) * | 2004-11-07 | 2009-12-02 | Timothy F Guilford | Liposomal formulation for oral administration of glutathione (reduced) |
| US8349359B2 (en) | 2004-11-07 | 2013-01-08 | Your Energy Systems, LLC | Liposomal formulation for oral administration of glutathione (reduced) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2609393A1 (en) | Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared | |
| FR2627385A1 (en) | Dermatological and cosmetic compsns. - contain lipid phase and nitrogenous cpd. esp. amino acid, oligo or polypeptide | |
| EP2496242B1 (en) | Use of yeast peptide hydrolysate as an active agent for strengthening hair | |
| WO2001045648A2 (en) | Use of a vaccinium-type extract as an anti-glycation agent | |
| EP1406589B1 (en) | Cosmetic or dermatological use of peptides for promoting adhesion between skin cells | |
| WO2000058347A1 (en) | Cosmetic or dermopharmaceutical compositions containing tripeptide n-biotinyl-gly-his-lys for the prevention, reduction or suppression of hair loss and stimulation of regrowth | |
| WO2001043701A2 (en) | Cosmetic or dermopharmaceutical compositions containing the n-palmytoyl-gly-hys-lys tripeptide | |
| FR2837098A1 (en) | Cosmetic or pharmaceutical composition, useful for, e.g. combating skin aging and accelerating cicatrization, comprises laminin mimetic pentadecapeptide having cellular adhesion promoting action | |
| EP1406651B1 (en) | Cosmetic or dermatological use of a peptide for promoting adhesion between skin cells | |
| FR2925325A1 (en) | Use of rapeseed (Brassica napus) peptide hydrolysate, as active ingredient to activate the synthesis of aquaporins with other active ingredients, and in cosmetic or nutraceutical composition to improve hydration and barrier function of skin | |
| FR2925332A1 (en) | USE OF A SPOTLIGHT HYDROLYZATE AS AN ACTIVATOR ACTIVE INGREDIENT OF AQUAPORIN SYNTHESIS | |
| FR2925329A1 (en) | Use of oats (Avena sativa L.) peptide hydrolysate, as active ingredient to activate the synthesis of aquaporins with other active ingredients, and in cosmetic/nutraceutical composition to improve hydration and barrier function of skin | |
| FR2925330A1 (en) | Use of potato (Solanum tuberosum) peptide hydrolysate, as active ingredient to activate the synthesis of aquaporins with other active ingredients and in cosmetic/nutraceutical composition to improve hydration and barrier function of skin | |
| EP2240505B1 (en) | Peptide for activating aquaporin synthesis | |
| FR2925331A1 (en) | Use of bean (Vicia faba L.) peptide hydrolysate, as active ingredient to activate the synthesis of aquaporins with other active ingredients and in cosmetic/nutraceutical composition to improve hydration and barrier function of skin | |
| EP2558061A1 (en) | Use of a peptide hydrolysate of pea as moisturizing active agent | |
| WO2009106715A2 (en) | Peptide derived from a protein of the aquaporin family and cosmetic and/or pharmaceutical composition containing same | |
| EP2523967B1 (en) | Novel anti-ageing peptides modulating survivin and compositions including same | |
| EP2086564A1 (en) | Peptide-containing pharmaceutical and/or cosmetic composition | |
| FR2729079A1 (en) | Cosmetic compsn contg synthetic ceramide and protease | |
| FR2827171A1 (en) | Use of an enzymatic hydrolysate of salmon eggs for preventing or treating the effects of aging caused by physiology or sunlight | |
| WO2008145855A1 (en) | Pharmaceutical and/or cosmetic composition containing a cytochrome c-activating active ingredient | |
| EP2496308B1 (en) | Use of a peptide hydrolysate from maize as active agent stimulating hair growth | |
| WO2008015344A2 (en) | Dermatological and/or cosmetic composition containing polypeptides or peptides of the protein slc24a5 | |
| FR3006588A1 (en) | PEPTIDE SOYBEAN EXTRACT AND ITS COSMETIC USE TO STRENGTHEN THE STRUCTURE OF THE HAIR |